Q-omics provides the consensus-scored STING1 profile across patient tissues and cancer cell-line models. STING1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, STING1 is differentially expressed in 14, with the highest sampling consensus in THCA. Additionally, STING1 protein abundance shows 19,938 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRP, THCA, and LSCC as cancer lineages where STING1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STING1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STING1 survival associations across molecular data types. STING1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (2) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STING1 RNA expression–survival associations across cancer types. High STING1 expression shows unfavorable associations in KIRP, UVM, LGG and STAD, but favorable associations in HNSC and CESC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for STING1 RNA expression.
This table summarizes STING1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for STING1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STING1 shows lower tumor expression in LUSC and LUAD and higher tumor expression in THCA, KIRC, COAD and STAD. The THCA box plot shows higher STING1 RNA expression in tumor versus normal tissue (log2 FC = +1.835, t-test p < 0.001).
This table shows molecular features associated with STING1 in patient tissues and cancer cell lines. In patient samples, STING1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, STING1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Lymphoma.
